Pharma Marketing Network

A conversation with Alan Topin, President of Topin & Associates, about what he has called the 'Doctor-Patient Disconnect' and the role of pharmaceutical marketers in overcoming that disconnect by facilitating the conversation. Topin will also be a member of a panel moderated by PharmaGuy at the Social Media for Pharma conference. The panel is titled 'Getting To The Heart Of What Patients And HCPs Really Want And Need To Win Trust And Help Bridge The Widening Gap Between Patient And Prescriber.'

At the recent Selling Sickness conference in Washington, DC. Sydney Wolfe, MD (Public Citizen), gave a rousing keynote presentation. As I reported last week,...

I am a fish out of water here at the 2013 Selling Sickness conference in Washington, D.C. Although the theme of the conference --...

When I wrote the Pharma Marketing News article "Some Unregulated Physician Smartphone Apps May Be Buggy" back in January 2012, I reported that Pfizer...

Jennifer Miller, a fellow at the Edmund J Safra Center for Ethics at Harvard University and president of Bioethics International, a non-profit that advises educational programs on ethical issues on medicine and healthcare, is trying to develop the industry equivalent of a 'Good Housekeeping Seal of Approval.' This article summarizes her ideas and presents opinions of several naysayers.

Has the drug industry systematically violated PhRMA's DTC Principles? Is pharma self-regulation a deception meant to deflect criticism and block new FDA regulations? The answer is

As with Web sites in the early days, it is difficult today for users of mobile health apps to be assured that the apps are reliable, accurate, based on valid information, and adequately safeguard users' information. In many ways, we are living through another digital

As with Web sites in the early days, it is difficult today for users of mobile health apps to be assured that the apps are reliable, accurate, based on valid information, and adequately safeguard users' information. In many ways, we are living through another digital

Welcome to Volume 12, Issue #2 (20 February 2013) of Pharma Marketing News.

Daniel Vasella, chairman and chief executive of Novartis, should not have accepted a $78m payment, according to th Financial Times (here). Mr Vasella “has agreed...